Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced a partnership with Gore Range Capital LLC ("Gore Range Capital") (Dallas, TX, USA) for establishment of a joint venture, Sagesse...
Prestige Biopharma’s Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion from the EMA
Following approval by the European Commission, Prestige Biopharma's Herceptin biosimilar Tuznue® would become the first biosimilar from a Singaporean company to be authorized in the European Union. SINGAPORE, Aug. 1, 2024 /PRNewswire/ -- Prestige Biopharma, a pioneer in biopharmaceuticals, announced that the Committee for Medicinal Products for Human Use (CHMP)...
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement. The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs, small nucleic acids, and CGT (cell and gene therapy) drugs. The goal of this partnership is to advance the innovation of the Chinese pharmaceutical...
SURGLASSES Announces Successful First Clinical Implementation of Caduceus S AR Surgical Navigation System in Thailand
ONTARIO, Calif., July 31, 2024 /PRNewswire/ -- Leading augmented reality (AR) medical technology company SURGLASSES today announced that, in collaboration with exclusive distributor Goodlifeintertrade.co. Ltd., it has successfully registered and clinically implemented its AR-based Caduceus S surgical navigation system in Thailand. This groundbreaking system is designed to assist various minimally invasive surgeries, significantly enhancing surgical precision and patient outcomes....
Angel Yeast Driving Green Transformation Though Technological Innovation
SHANGHAI, July 31, 2024 /PRNewswire/ -- Angel Yeast (en.angelyeast.com) (SH600298), a global leader in yeast manufacturing, is accelerating green transformation in its factory workshops by implementing a series of intelligent, automated, and sustainable technologies that not only improves production efficiency, but also contributes to the sustainable development of the industry. In the...
PROCESSED RED MEAT RAISES THE RISK OF DEMENTIA; SWAPPING IT FOR NUTS AND BEANS MAY LOWER RISK
Four-decade study of more than 130,000 people measured the risk of your morning bacon or ballgame hot dog Key Takeaways Eating about two servings per week of processed red meat raises the risk of dementia by 14% compared to those who eat less than approximately three servings a month. Swapping a...
Kexing Biopharm’s Albumin-bound Paclitaxel Granted EU Market Approval
SHENZHEN, China, July 31, 2024 /PRNewswire/ -- On July 28 2024, Kexing Biopharm announced European Commission approval of Apexelsin®, the generic drug to Bristol Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel). Apexelsin® is developed by WhiteOak Pharmaceutical B.V. and Kexing Biopharm is in charge of the commercialization of this product out of US. Nanoparticle albumin-bound paclitaxel offers significant advantages for clinical...
JelloX Biotech collaborates with Mayo Clinic to develop AI enhanced 3D pathology imaging technology
HSINCHU, July 31, 2024 /PRNewswire/ -- JelloX Biotech Inc. ('JelloX') is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to further develop and validate their 3D digital imaging and AI analysis technology. JelloX previously participated in the fifth cohort of the Mayo Clinic and Arizona...
Fapon Delivers Customized IVD Solutions for the US Market at ADLM 2024
CHICAGO, July 31, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is showcasing its innovative IVD total solutions at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), from July 28 to August 1 in Chicago. Committed to supporting local partners, we deliver customized solutions with advanced...
FDA Grants Orphan Drug Designation (ODD) Status to Zymedi’s ZMA001 for Pulmonary Arterial Hypertension
INCHEON, South Korea, July 31, 2024 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA). Pulmonary arterial hypertension is an inflammatory vascular disease characterized by the remodeling and narrowing of pulmonary arterioles...
